1. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5:95–102. PMID:
17234558.
Article
2. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132:66–75. PMID:
17241860.
Article
3. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut. 2000; 47:410–414. PMID:
10940280.
Article
4. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987; 92:1894–1898. PMID:
3569765.
Article
5. Hibi T. Ministry of Health, Labour and Welfare. Atlas of endoscopy in inflammatory bowel disease. Research Group for Intractable Inflammatory Bowel Disease (Watanabe Group). Health and labour science research grants from the Japanese Ministry of Health, Labour and Welfare and research on measures for intractable disease: 2007 research report. Tokyo: Ministry of Health, Labour and Welfare;2008. p. 423–457.
6. Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010; 16:1567–1574. PMID:
20049950.
Article
7. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci. 1995; 40:296–304. PMID:
7851193.
Article
8. Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008; 27:1094–1102. PMID:
18363894.
Article
9. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol. 2007; 21:827–834. PMID:
18080055.
Article
10. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005; 100:2478–2485. PMID:
16279903.
Article
11. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 48 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009; 137:1934–1943.e3. PMID:
19766640.
Article